Items where authors include "Buch, M.H."

Article

Abani, O., Abbas, A., Abbas, F. et al. (8021 more authors) (2025) Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. eClinicalMedicine, 81. 103080. ISSN 2589-5370

Denton, C.P., De Lorenzis, E., Roblin, E. et al. (27 more authors) (2024) The 2024 British Society for Rheumatology guideline for management of systemic sclerosis. Rheumatology. keae394. ISSN 1462-0324

Denton, C.P., De Lorenzis, E., Roblin, E. et al. (27 more authors) (2024) The 2024 British Society for Rheumatology guideline for management of systemic sclerosis—executive summary. Rheumatology. keae390. ISSN 1462-0324

Shukla, R., Wakefield, R. orcid.org/0000-0001-5352-8683, Tan, A.L. orcid.org/0000-0002-9158-7243 et al. (3 more authors) (2024) OA02 Longitudinal high throughput proteomics identifies novel proteins associated with inflammation and future response in new-onset, treatment-naïve rheumatoid arthritis. Rheumatology, 63 (Supplement_1). keae163.002. ISSN 1462-0324

Álvarez-Hernández, M.P. orcid.org/0000-0002-9972-1312, Allanore, Y., Andrade, I. et al. (9 more authors) (2024) Attitudes and barriers to pulmonary arterial hypertension screening in systemic sclerosis patients: A survey of UK-based rheumatologists. Journal of Scleroderma and Related Disorders. ISSN 2397-1983

Sandercock, P., Darbyshire, J., DeMets, D. et al. (2050 more authors) (2024) Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Nature Communications, 15. 924. ISSN 2041-1723

Abani, O., Abbas, A., Abbas, F. et al. (7989 more authors) (2023) Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Diabetes & Endocrinology, 11 (12). pp. 905-914. ISSN 2213-8587

Abani, O., Abbas, A., Abbas, F. et al. (8104 more authors) (2023) Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 401 (10387). pp. 1499-1507. ISSN 0140-6736

Dumitru, R.B., Bissell, L., Erhayiem, B. et al. (8 more authors) (2023) Subclinical Systemic Sclerosis Primary Heart Involvement by Cardiovascular Magnetic Resonance Shows No Significant Interval Change. ACR Open Rheumatology, 5 (2). pp. 71-80. ISSN 2578-5745

Lescoat, A., Murphy, S.L., Chen, Y.T. et al. (5 more authors) (2022) Symptom experience of limited cutaneous systemic sclerosis from the Patients’ perspective: A qualitative study. Seminars in Arthritis and Rheumatism, 52. 151926. ISSN 0049-0172

Corinaldesi, C., Ross, R.L., Abignano, G. orcid.org/0000-0002-1479-0133 et al. (8 more authors) (2021) Muscle Damage in Systemic Sclerosis and CXCL10: The Potential Therapeutic Role of PDE5 Inhibition. International Journal of Molecular Sciences, 22 (6). 2894. ISSN 1661-6596

Lescoat, A., Roofeh, D., Townsend, W. et al. (6 more authors) (2021) Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: a scoping review protocol. BMJ Open, 11 (3). e044765. ISSN 2044-6055

Lescoat, A., Murphy, S.L., Roofeh, D. et al. (17 more authors) (2020) Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. Journal of Scleroderma and Related Disorders, 6 (1). 66 -76. ISSN 2397-1983

Peytrignet, S., Denton, C.P., Lunt, M. et al. (60 more authors) (2018) Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. Rheumatology, 57 (2). pp. 370-381. ISSN 1462-0324

Herrick, A.L., Pan, X., Peytrignet, S. et al. (61 more authors) (2017) Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Annals of the Rheumatic Diseases. ISSN 0003-4967

Buch, M.H., Conaghan, P., Quinn, M.A. et al. (3 more authors) (2004) True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin α? Annals of the Rheumatic Diseases, 63 (10). pp. 1344-1346. ISSN 0003-4967

Proceedings Paper

Shukla, R., Dumitru, R.B., Erhayiem, B. et al. (5 more authors) (2024) P143 High throughput multiplex assay identifies clinically meaningful clusters in systemic sclerosis patients with low cardiovascular risk and no history of heart disease. In: Rheumatology. British Society for Rheumatology Annual Conference 2024, 24-26 Apr 2024, Liverpool, United Kingdom. Oxford University Press .

Cheung, W.C., Shukla, R., Dumitru, R. et al. (8 more authors) (2023) POS0627 Blood-Based Protein Biomarkers Are Associated With Subclinical Cardiovascular Abnormalities As Defined By Cardiovascular Magnetic Resonance Imaging In Systemic Sclerosis (Ssc) Patients. In: Annals of the Rheumatic Diseases (ARD). EULAR 2023 European Congress of Rheumatology, 31 May - 03 Jun 2023, Milan, Italy. BMJ Publishing Group , pp. 587-588.

Lescoat, A., Chen, Y., Murphy, S.L. et al. (22 more authors) (2023) POS1258 Results from a nominal group technique exercise for the creation of a combined response index for limited cutaneous systemic sclerosis: The CRISTAL project. In: Annals of the Rheumatic Diseases. EULAR 2023 - European Congress of Rheumatology, 31 May - 03 Jun 2023, Milan, Italy. BMJ Publishing Group , pp. 971-972.

Dumitru, R.B., Goodall, A., Broadbent, D. et al. (6 more authors) (2020) FRI0236 First pilot study of T1 mapping MRI with ECV measurement of peripheral muscle in systemic sclerosis patients shows diffuse fibrosis. In: Annals of the Rheumatic Diseases. EULAR 2020 - European E-Congress of Rheumatology, 03-06 Jun 2020, Online. BMJ , p. 702.